Multiple Sclerosis Pipeline Landscape Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook
Key Takeaways from the Multiple Sclerosis Pipeline Report
In July 2025, Novartis Pharmaceuticals announced a study is divided into a Core Part and Extension Part. The Core Part is a 24-month, double-blind, triple dummy, randomized, 3-arm active-controlled in children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). The Extension Part is 60-month (5 year) open label (except for first 12 weeks transition which will remain double-blind) treatment for patients who complete the Core Part of the study and meet all inclusion/exclusion criteria.
In July 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment.
The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others.
Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.
Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment
Multiple sclerosis Emerging Drugs Profile
IMU-838: Immunic Therapeutics
Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties.
BIIB091: Biogen
BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis.
IMCY-0141: ImCyse
IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis.
NeuroVax: Immune Response BioPharma
NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients.
The Multiple Sclerosis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.
Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market
Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs
Multiple Sclerosis Companies
Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others.
Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Multiple Sclerosis Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives
Scope of the Multiple Sclerosis Pipeline Report
Coverage- Global
Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others.
Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.
Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
Multiple sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Multiple sclerosis – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
IMU-838: Immunic Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BIIB091: Biogen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NeuroVax: Immune Response BioPharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Multiple sclerosis Key Companies
Multiple sclerosis Key Products
Multiple sclerosis- Unmet Needs
Multiple sclerosis- Market Drivers and Barriers
Multiple sclerosis- Future Perspectives and Conclusion
Multiple sclerosis Analyst Views
Multiple sclerosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Geo Group Expands Credit Facility and Lowers Debt
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Geo Group ( (GEO)) has issued an update. On July 14, 2025, The GEO Group, Inc. announced an amendment to its Credit Agreement, increasing its revolving credit facility from $310 million to $450 million and extending its maturity to July 14, 2030. The amendment also lowered interest rates and increased the company's capacity to make restricted payments over the next five years. Prior to this, GEO repaid $132 million of its Term Loan B and plans to use proceeds from the sale of a facility to reduce further debt. These actions are expected to lower GEO's total net debt to approximately $1.47 billion, positioning the company for potential future capital returns and demonstrating growing support from banking partners. The most recent analyst rating on (GEO) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Geo Group stock, see the GEO Stock Forecast page. Spark's Take on GEO Stock According to Spark, TipRanks' AI Analyst, GEO is a Neutral. The overall stock score of 64 reflects a complex blend of positive strategic initiatives and financial challenges. The company's future growth potential, highlighted by new contracts and debt reduction plans, is offset by current high leverage and profitability concerns. Technical indicators and high valuation ratios suggest caution in the short term, while corporate actions support a strategic repositioning for future success. To see Spark's full report on GEO stock, click here. More about Geo Group The GEO Group, Inc. is a leading diversified government service provider specializing in the design, financing, development, and support services for secure facilities, processing centers, and community reentry centers across the United States, Australia, South Africa, and the United Kingdom. The company offers enhanced in-custody rehabilitation, post-release support, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO operates 98 facilities with approximately 77,000 beds and employs around 19,000 people worldwide. Average Trading Volume: 2,990,306 Technical Sentiment Signal: Buy Current Market Cap: $3.54B See more data about GEO stock on TipRanks' Stock Analysis page.
CTV News
3 hours ago
- CTV News
Netflix shares fall as weak U.S. dollar-driven forecast fails to impress
Netflix shares declined more than four per cent on Friday as some investors were disappointed by a revenue forecast that was driven more by a weaker dollar than strong demand for the streamer's content. Expectations were running high for the streaming giant, after its shares nearly doubled in value in the past year and viewers binged on content such as the final season of South Korean survival drama 'Squid Game' in the second quarter. But executives said much of the increase in the annual forecast was driven by weakness in the U.S. dollar, now predicting revenue of between US$44.8 billion and $45.2 billion, up from $43.5 billion to $44.5 billion previously. 'When your shares are already binge-watched to perfection, the earnings beat needed to be stronger to satisfy expectations,' said Michael Ashley Schulman, chief investment officer at Running Point Capital Advisors. 'Instead, some sold on the good news and maybe questioned whether the positive FX effect will be there a few quarters down the road.' A crackdown on password-sharing, more sports content and its ad-supported tier helped Netflix draw tens of millions of new viewers in 2024. But the company stopped reporting subscriber numbers earlier this year, shifting focus to metrics like revenue and profit, a move that has raised concerns about growth. The streaming giant, whose $517-billion market value is more than the combined worth of Disney, Comcast and Warner Bros Discovery, posted quarterly earnings per share of $7.19, beating estimates of $7.08, according to data compiled by LSEG. 'A strong content slate in the second half of the year and growing traction for its advertising efforts could help support continued revenue gains in the third quarter and beyond,' said Seth Shafer, principal analyst at S&P Global Market Intelligence Kagan. At least 16 analysts raised their price targets on the stock following the results, bringing the median target to $1,385, as per data compiled by LSEG. (Reporting by Joel Jose, Siddarth S and Harshita Mary Varghese in Bengaluru; Editing by Leroy Leo)
Globe and Mail
4 hours ago
- Globe and Mail
ESG Reporting Software Market Expected to Reach USD 3.92 Billion by 2032
Growing Emphasis on Risk Management and Mitigation to Propel Global Market Beyond US 3.92 Billion by 2032 at 17.2% CAGR – Coherent Market Insights According to Coherent Market Insights, The Global ESG Reporting Software Market is estimated to be valued at USD 1.29 Bn in 2025 and is expected to reach USD 3.92 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.2% from 2025 to 2032. The market is projected to experience substantial growth during the forecast period, driven by rising organizational awareness of sustainability and Environmental, Social, and Governance (ESG) reporting. The growing emphasis on measuring, monitoring, and disclosing ESG performance is fueling demand for dedicated ESG software solutions. Furthermore, investors are placing greater importance on ESG considerations when making investment decisions, further accelerating market expansion. Global ESG Reporting Software Market Key Takeaways According to Coherent Market Insights (CMI), the global ESG reporting software market size is slated to increase at a robust CAGR of 17.2%, reaching USD 1.29 Bn in 2025 and USD 3.92 Bn in 2025. Based on offering, software segment is expected to account for nearly four-fifths of the global ESG reporting software market share in 2025. By deployment type, cloud segment is set to hold a prominent market share of nearly 3/5 in 2025. As per CMI's new ESG reporting software market analysis, North America is projected to maintain its monopoly, accounting for over two-fifths of the global market share in 2025. Asia Pacific ESG reporting software industry is poised to register fastest growth during the forecast period. Regulatory Pressure and Compliance Requirements Fuelling Market Growth Coherent Market Insights' latest ESG reporting software market research report highlights major factors driving industry growth. Increasing regulatory requirements and compliance mandates is one such key factor. Governments and regulatory bodies globally are introducing stringent ESG regulations. A few prime examples include the SEC climate disclosure rules in the United States and EU's CSRD. These mandates are compelling companies to adopt ESG reporting tools, thereby driving market growth. ESG reporting software enables organizations to manage, track, and report their ESG metrics. It makes it easier for businesses to monitor their sustainability efforts and comply with regulations by automating data collection, analysis, and reporting processes. High Implementation Costs and Data Security Concerns Limiting Market Growth The future ESG reporting software market outlook looks bright. However, growing concerns over data privacy and high implementation costs could somewhat constrain market expansion over the forecast period. Implementing ESG reporting software with existing systems like CRM and ERP can be complex and expensive. This deters some small and medium enterprises from opting for these ESG reporting platforms, dampening overall ESG reporting software market demand. Moreover, ESG platforms handle sensitive internal data, making them vulnerable to breaches, cyberattacks, and data misuse. These security concerns could also hamper the ESG reporting software market growth in the coming years. Rising Emphasis on Risk Management Creating Growth Opportunities The growing focus on risk management and mitigation is expected to create lucrative growth opportunities for ESG reporting software companies. This is because ESG reporting software empowers organizations to identify, monitor, and mitigate various ESG-related risks, including climate change impacts and regulatory non-compliance. Companies can use ESG reporting software to track progress on their sustainability initiatives and identify areas for improvement. Similarly, it enables them to proactively manage potential risks, strengthen internal governance, and enhance transparency with stakeholders. Impact of AI on the ESG Reporting Software Market Artificial intelligence (AI) is transforming ESG reporting software from a compliance burden into a strategic tool. This advanced technology elevates transparency, trust, and operational agility in corporate sustainability. The infusion of AI into the ESG reporting software landscape is accelerating a shift from manual, retrospective compliance toward proactive, strategic sustainability management. This shift enables organizations to effectively manage sustainability goals and make informed decisions in real time. AI-powered platforms are streamlining data collection and validation. They significantly reduce errors and shorten reporting timelines. This heightened efficiency is vital as global regulatory frameworks like the EU's CSRD and SEC climate rules raise the bar for standardized, audit-ready ESG disclosures. Emerging ESG Reporting Software Market Trends There is a growing trend of using artificial intelligence and machine learning in ESG reporting platforms. These advanced technologies significantly improve data accuracy, automate data gathering, and enhance predictive insights for ESG performance. Cloud-based ESG tools are gaining immense traction globally as they offer scalability, accessibility, and lower upfront costs. Rising adoption of these cloud-based solutions is expected to boost the ESG reporting software market value during the assessment period. Increasing investor demand for transparency is acting as a catalyst, triggering growth of the ESG reporting software market. Stakeholders, asset managers, and institutional investors increasingly prioritize ESG performance when making investment decisions. This is where ESG reporting software steps in, helping companies meet transparency expectations. Many organizations are voluntarily committing to net-zero targets, reducing their carbon footprints, and enhancing governance practices. These corporate sustainability initiatives are driving increased demand for ESG reporting software as it supports goal setting, performance tracking, and reporting progress toward sustainability commitments. Analyst's View 'The global ESG reporting software industry is set for robust growth, owing to increasing regulatory requirements, heightened compliance demands, and a growing focus on corporate sustainability,' said Monica Shevgan, a senior analyst at CMI. Competitor Insights Key companies in the ESG reporting software market report: - Wolters Kluwer - Cority - Diligent Corporation - Intelex Technologies - Brightest Inc. - Benchmark Digital Partners LLC - Workiva - Nasdaq, Inc. - UL Solutions - Salesforce, Inc. - Greenstone+ Ltd. - Sphera - Novisto - SAP - Emex Software Ltd. Buy this Complete Business Research Report: Key Developments In April 2025, Zevero launched a new AI-powered ESG reporting tool (ESG Disclosure Reporting Solution) to streamline ESG disclosures using AI-driven data extraction from documents. The new solution supports major global frameworks, including CDP, B Corp, and CSRD. In May 2025, SAP launched new sustainability data management solutions to meet evolving needs of customers. These new solutions are aimed at helping companies collect, manage, and govern sustainability data across their value chains. About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
